Neoadjuvant therapy as a platform for drug development: Current controversies and regulatory perspectives

Laleh Amiri-Kordestani, Julia A. Beaver, Patricia Cortazar

Research output: Contribution to journalArticlepeer-review

Abstract

This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume29
Issue number11
StatePublished - Nov 15 2015
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant therapy as a platform for drug development: Current controversies and regulatory perspectives'. Together they form a unique fingerprint.

Cite this